SP-101 and doxorubicin Cohort 1
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Spirovant Sciences, Inc.
Overview
SP-101 and doxorubicin Cohort 1 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
SP-101 and doxorubicin Cohort 1 clinical trials
Explore related
Medical disclaimer. This page summarizes research about SP-101 and doxorubicin Cohort 1 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.